Ep. 358 - Europe's biotech challenge

Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a fresh challenge for European biotech on top of falling equity and R&D investment in Europe and a complex drug pricing landscape. On a special edition of the BioCentury This Week podcast on the eve of the 26th Bio€quity Europe conference, EQT Life Sciences' Christoph Broja and Prague Bio CEO Petra Kinzlová join BioCentury’s analysts to discuss the challenges faced by European biotech today and what the best strategy is to compete in this new era.Kinzlová also describes a growing biotech ecosystem in the Czech Republic, which will host Bio€quity Europe May 4-6.View full story: https://www.biocentury.com/article/659002#EuropeanBiotech #ClinicalDevelopmentSpeed #ChinaBiotech #DrugPricing #BiotechInvestment01:10 - Bio€quity Europe Preview04:32 - Czech Innovation Hubs09:52 - Pricing, Trials, Funding13:07 - Fixing Trial Bottlenecks17:49 - Pension Capital and RiskTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text